E-therapeutics Adds New Board Member
This article was originally published in Scrip
E-Therapeutics PLC. has appointed Trevor Mervyn Jones as non-executive director. Rajesh Chopra will be resigning as non-executive director to return to academic research. Currently Jones is chair of the international clinical research organisation (CRO), Simbec-Orion Group Ltd. and Welsh investment company, Arthurian Life Sciences Ltd. Previously he was director of Allergan Inc. and R&D director of The Wellcome Foundation and has also held advisory and regulatory roles. He was director general of the Association of the British Pharmaceutical Industry (ABPI), board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Jones was also a member of the UK government regulatory agency, The Medicines Commission for 12 years.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.